Older age (≥60 years)1-3
While RSV-related infections usually present as mild cold-like symptoms in adults, some cases may lead to more serious respiratory complications, hospitalisation and death, particularly in older adults and those with underlying conditions1
A large prospective study estimated the incidence of RSV-associated hospitalisation in two regions of New York State, USA, 2017–2020. N=1099 cases:2
This graph was independently created for GSK from the original data
Comorbidity | Incidence rate ratio* | |
---|---|---|
Rochester |
NYC | |
COPD | ||
50-64y |
6.35 |
6.30 |
≥65y |
13.41 |
3.51 |
Asthma |
||
50-64y | 2.34 | 3.60 |
≥65y | 2.52 | 2.27 |
Diabetes | ||
50-64y | 3.36 | 3.58 |
≥65y | 6.44 | 2.35 |
CAD | ||
50-64y | 3.74 | 4.41 |
≥65y | 6.46 | 3.75 |
CHF | ||
60-79y | 7.63 | 5.86 |
≥80y | 3.99 | 5.40 |
*Ratio of rate among people with each comorbidity versus those without it, in the surveillance area population
In older adults hospitalised with RSV, the risk of severe outcomes is comparable to those hospitalised with influenza
This graph was independently created for GSK from the original data
CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; NYC, New York City; RSV, respiratory syncytial virus
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
©2023 GSK group of companies. All rights reserved.
July 2024 | NX-GB-GVU-WCNT-230008 (V2.0)